The European Commission (EC) has approved sugemalimab (brand name: Cejemly®) in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no ...

and antibody dependent cellular phagocytosis (ADCP). Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan, a polysaccharide found in the extracellular matrix.